Imatinib Plasma Monitoring-Guided Dose Modification for Managing Imatinib-Related Toxicities in Gastrointestinal Stromal Tumor Patients

Imatinib, the first-line treatment in patients with advanced gastrointestinal stromal tumors (GIST), is generally well tolerated, although some patients have difficulty tolerating the standard dose of 400 mg/day. Adjusting imatinib dosage by plasma level monitoring may facilitate management of patie...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Yoon, Shinkyo, Ryu, Min-Hee, Yoo, Changhoon, Beck, Mo Youl, Ryoo, Baek-Yeol, Kang, Yoon-Koo
Формат: Artigo
Язык:Inglês
Опубликовано: The Korean Academy of Medical Sciences 2013
Предметы:
Case Report
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3744717/
https://ncbi.nlm.nih.gov/pubmed/23960456
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3346/jkms.2013.28.8.1248
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы